Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 4, 2013, Pages 437-440

  Lee, Elliot ^a   Edward, Selwan ^a   Singal, Amit G ^b   Lavieri, Mariel S ^a   Volk, Michael ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AUROC; Biomarker; Cancer Detection; HALT C Trial; Surveillance

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; SMOKING; THROMBOCYTE COUNT;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84875370395     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.029     Document Type: Article

References (10)

1. Fast facts 2010, Globocan, International Agency for Research on Cancer, Lyon, France.
2. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
3. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513. 521.e1-6.
4. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
5. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
6. Imaeda T., Doi H. A retrospective study on the patterns of sequential fluctuation of serum alpha-fetoprotein level during progression from liver cirrhosis to hepatocellular carcinoma. J Gastroenterol Hepatol 1992, 7:132-135.
7. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-680.
8. Lee E., Lavieri M.S., Volk M. Evaluating hypothetical screening policies on historical patient data. Proceedings of INFORMS Data Mining and Health Informatics Workshop 2012.
9. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
10. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.